{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:25:03Z","timestamp":1775809503013,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670879"],"award-info":[{"award-number":["81670879"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To evaluate 5-year outcomes of anti-vascular endothelial growth factor (VEGF) monotherapy and combination therapy of anti-VEGF agents and photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) in a real-world Chinese population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective study. Fifty-three eyes of 46 patients with subtype 1 and 2 PCV followed up for at least 60\u2009months were grouped into three regimens: anti-VEGF monotherapy, PDT combining with anti-VEGF therapy initially, and PDT combining with deferred anti-VEGF therapy. Main outcome measure was best-corrected visual acuity (BCVA) using logarithm of minimal angle of resolution (logMAR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean BCVA of eyes with subtype 1 PCV (<jats:italic>n<\/jats:italic>\u2009=\u200928) deteriorated from 0.69 logMAR at baseline to 1.25 logMAR at months 60 (<jats:italic>P<\/jats:italic>\u2009=\u20090.001), while the mean BCVA of eyes with subtype 2 PCV (<jats:italic>n<\/jats:italic>\u2009=\u200925) sustained stable from 0.62 logMAR at baseline to 0.57 at months 60 (<jats:italic>P<\/jats:italic>\u2009=\u20090.654). No significant differences of visual outcomes were found between the 3 treatment regimens for subtype 1 PCV. Anti-VEGF monotherapy and initial combination treatment had better visual outcomes in eyes with subtype 2 PCV than deferred combination group during part of follow-up significantly. Initial combination group needed a less number of PDT than deferred combination group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Compared with subtype 1 PCV, subtype 2 PCV has a more favorable visual outcome in real world. All the regimens presented unfavorable visual outcomes for subtype 1 PCV. Anti-VEGF monotherapy and initial combination therapy should be superior to deferred combination therapy in the long-term management of subtype 2 PCV. Prospective randomized studies of larger size are needed to determine the long-term efficacy and safety of various treatment for PCV in real world.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-019-1245-4","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T17:03:49Z","timestamp":1574355829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study"],"prefix":"10.1186","volume":"19","author":[{"given":"Jingyuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhen","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-5058","authenticated-orcid":false,"given":"Youxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"issue":"11","key":"1245_CR1","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1016\/j.ophtha.2014.06.016","volume":"121","author":"Y Li","year":"2014","unstructured":"Li Y, You QS, Wei WB, Xu J, Chen CX, Wang YX, Xu L, Jonas JB. Polypoidal choroidal vasculopathy in adult chinese: the Beijing eye study. Ophthalmology. 2014;121(11):2290\u20131.","journal-title":"Ophthalmology"},{"issue":"8","key":"1245_CR2","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1097\/IAE.0b013e31820d3f28","volume":"31","author":"H Bessho","year":"2011","unstructured":"Bessho H, Honda S, Imai H, Negi A. Natural course and funduscopic findings of polypoidal choroidal vasculopathy in a Japanese population over 1 year of follow-up. Retina (Philadelphia, Pa). 2011;31(8):1598\u2013602.","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"12","key":"1245_CR3","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00417-015-2933-2","volume":"253","author":"CM Cheung","year":"2015","unstructured":"Cheung CM, Yang E, Lee WK, Lee GK, Mathur R, Cheng J, Wong D, Wong TY, Lai TY. The natural history of polypoidal choroidal vasculopathy: a multi-center series of untreated Asian patients. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2015;253(12):2075\u201385.","journal-title":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"},{"issue":"1","key":"1245_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","volume":"10","author":"LA Yannuzzi","year":"1990","unstructured":"Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina (Philadelphia, Pa). 1990;10(1):1\u20138.","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"2","key":"1245_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/ceo.13114","volume":"46","author":"KK Dansingani","year":"2018","unstructured":"Dansingani KK, Gal-Or O, Sadda SR, Yannuzzi LA, Freund KB. Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of 'expanded spectra' - a review. Clin Exp Ophthalmol. 2018;46(2):189\u2013200.","journal-title":"Clin Exp Ophthalmol"},{"issue":"5","key":"1245_CR6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","volume":"125","author":"CMG Cheung","year":"2018","unstructured":"Cheung CMG, Lai TYY, Ruamviboonsuk P, Chen SJ, Chen Y, Freund KB, Gomi F, Koh AH, Lee WK, Wong TY. Polypoidal Choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology. 2018;125(5):708\u201324.","journal-title":"Ophthalmology"},{"issue":"4","key":"1245_CR7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/IAE.0b013e3182852446","volume":"33","author":"AH Koh","year":"2013","unstructured":"Koh AH, Chen LJ, Chen SJ, Chen Y, Giridhar A, Iida T, Kim H, Yuk Yau Lai T, Lee WK, Li X, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina (Philadelphia, Pa). 2013;33(4):686\u2013716.","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"8","key":"1245_CR8","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina (Philadelphia, Pa). 2012;32(8):1453\u201364.","journal-title":"Retina (Philadelphia, Pa)"},{"key":"1245_CR9","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2147\/OPTH.S171015","volume":"12","author":"K Takahashi","year":"2018","unstructured":"Takahashi K, Ohji M, Terasaki H, Honda S, Margaron P, Guerin T, Yuzawa M. Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study. Clinical ophthalmology (Auckland, NZ). 2018;12:1789\u201399.","journal-title":"Clinical ophthalmology (Auckland, NZ)"},{"issue":"4","key":"1245_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","volume":"156","author":"A Oishi","year":"2013","unstructured":"Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, Oh H, Kita M, Nagai T, Fujihara M, Bessho N, et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol. 2013;156(4):644\u201351.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"1245_CR11","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1097\/IAE.0000000000000526","volume":"35","author":"F Gomi","year":"2015","unstructured":"Gomi F, Oshima Y, Mori R, Kano M, Saito M, Yamashita A, Iwata E, Maruko R. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study. Retina (Philadelphia, Pa). 2015;35(8):1569\u201376.","journal-title":"Retina (Philadelphia, Pa)"},{"key":"1245_CR12","doi-asserted-by":"crossref","unstructured":"Wong TY, Ogura Y, Lee WK, Iida T, Chen SJ, Mitchell P, Gemmy Cheung CM, Zhang Z, Leal S, Ishibashi T. Efficacy and safety of Intravitreal Aflibercept for Polypoidal Choroidal vasculopathy: 2-year results of the PLANET study. Am J Ophthalmol. 2019.","DOI":"10.1016\/j.ajo.2019.02.027"},{"issue":"4","key":"1245_CR13","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ajo.2013.05.038","volume":"156","author":"HM Kang","year":"2013","unstructured":"Kang HM, Koh HJ. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;156(4):652\u201360.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1245_CR14","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1038\/s41598-019-39995-5","volume":"9","author":"K Nishikawa","year":"2019","unstructured":"Nishikawa K, Oishi A, Hata M, Miyake M, Ooto S, Yamashiro K, Miyata M, Tamura H, Ueda-Arakawa N, Takahashi A, et al. Four-year outcome of Aflibercept for Neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Sci Rep. 2019;9(1):3620.","journal-title":"Sci Rep"},{"issue":"4","key":"1245_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1089\/jop.2015.0073","volume":"32","author":"YS Chang","year":"2016","unstructured":"Chang YS, Kim JH, Kim KM, Kim JW, Lee TG, Kim CG, Cho SW. Long-term outcomes of anti-vascular endothelial growth factor therapy for Polypoidal Choroidal vasculopathy. Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics. 2016;32(4):219\u201324.","journal-title":"Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics"},{"key":"1245_CR16","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.2147\/OPTH.S178228","volume":"12","author":"M Ratanasukon","year":"2018","unstructured":"Ratanasukon M, Bhurayanontachai P, Jirarattanasopa P. Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences. Clinical ophthalmology (Auckland, NZ). 2018;12:2177\u201381.","journal-title":"Clinical ophthalmology (Auckland, NZ)"},{"issue":"3","key":"1245_CR17","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ajo.2012.09.020","volume":"155","author":"HM Kang","year":"2013","unstructured":"Kang HM, Kim YM, Koh HJ. Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;155(3):438\u2013447.e431.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1245_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00417-013-2433-1","volume":"252","author":"M Saito","year":"2014","unstructured":"Saito M, Iida T, Kano M, Itagaki K. Five-year results of photodynamic therapy with and without supplementary antivascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Graefe\u2019s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2014;252(2):227\u201335.","journal-title":"Graefe\u2019s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"},{"issue":"1","key":"1245_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/bjophthalmol-2017-310448","volume":"102","author":"T Hikichi","year":"2018","unstructured":"Hikichi T. Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2018;102(1):97\u2013101.","journal-title":"Br J Ophthalmol"},{"key":"1245_CR20","doi-asserted-by":"crossref","unstructured":"Jang JW, Kim JM, Kang SW, Kim SJ, Bae K, Kim KT: TYPICAL POLYPOIDAL CHOROIDAL VASCULOPATHY AND POLYPOIDAL CHOROIDAL NEOVASCULARIZATION. Retina (Philadelphia, Pa) 2018.","DOI":"10.1097\/IAE.0000000000002259"},{"issue":"6","key":"1245_CR21","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1111\/aos.12110","volume":"91","author":"A Kawamura","year":"2013","unstructured":"Kawamura A, Yuzawa M, Mori R, Haruyama M, Tanaka K. Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types. Acta Ophthalmol. 2013;91(6):e474\u201381.","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"1245_CR22","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1167\/iovs.14-16236","volume":"56","author":"G Coscas","year":"2015","unstructured":"Coscas G, Lupidi M, Coscas F, Benjelloun F, Zerbib J, Dirani A, Semoun O, Souied EH. Toward a specific classification of polypoidal choroidal vasculopathy: idiopathic disease or subtype of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2015;56(5):3187\u201395.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1245_CR23","doi-asserted-by":"crossref","unstructured":"Miyamoto N, Mandai M, Oishi A, Nakai S, Honda S, Hirashima T, Oh H, Matsumoto Y, Uenishi M, Kurimoto Y. Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study. Br J Ophthalmol. 2018.","DOI":"10.1136\/bjophthalmol-2018-312419"},{"issue":"3","key":"1245_CR24","first-page":"830","volume":"43","author":"U Schmidt-Erfurth","year":"2002","unstructured":"Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43(3):830\u201341.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"1245_CR25","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0161-6420(13)31079-3","volume":"101","author":"U Schmidt-Erfurth","year":"1994","unstructured":"Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology. 1994;101(12):1953\u201361.","journal-title":"Ophthalmology"},{"issue":"7","key":"1245_CR26","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1097\/IAE.0000000000001710","volume":"38","author":"P D'Souza","year":"2018","unstructured":"D'Souza P, Ranjan R, Babu U, Kanakath AV, Saravanan VR. INFLAMMATORY CHOROIDAL NEOVASCULAR MEMBRANE: Long-Term Visual and Anatomical Outcomes After Intravitreal Anti-vascular Endothelial Growth Factor Therapy. Retina (Philadelphia, Pa). 2018;38(7):1307\u201315.","journal-title":"Retina (Philadelphia, Pa)"},{"key":"1245_CR27","first-page":"908","volume":"20","author":"A Couturier","year":"2014","unstructured":"Couturier A, Bousquet E, Zhao M, Naud MC, Klein C, Jonet L, Tadayoni R, de Kozak Y, Behar-Cohen F. Anti-vascular endothelial growth factor acts on retinal microglia\/macrophage activation in a rat model of ocular inflammation. Mol Vis. 2014;20:908\u201320.","journal-title":"Mol Vis"},{"key":"1245_CR28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ajo.2016.03.024","volume":"166","author":"M Suzuki","year":"2016","unstructured":"Suzuki M, Nagai N, Shinoda H, Uchida A, Kurihara T, Tomita Y, Kamoshita M, Iyama C, Tsubota K, Ozawa Y. Distinct responsiveness to Intravitreal Ranibizumab therapy in Polypoidal Choroidal vasculopathy with single or multiple polyps. Am J Ophthalmol. 2016;166:52\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1245_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/IAE.0b013e318188c839","volume":"29","author":"P Cackett","year":"2009","unstructured":"Cackett P, Wong D, Yeo I. A classification system for polypoidal choroidal vasculopathy. Retina (Philadelphia, Pa). 2009;29(2):187\u201391.","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"7","key":"1245_CR30","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00417-010-1575-7","volume":"249","author":"J Hou","year":"2011","unstructured":"Hou J, Tao Y, Li XX, Zhao MW. Clinical characteristics of polypoidal choroidal vasculopathy in Chinese patients. Graefe\u2019s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2011;249(7):975\u20139.","journal-title":"Graefe\u2019s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1245-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-019-1245-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1245-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T02:05:19Z","timestamp":1605837919000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-019-1245-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1245"],"URL":"https:\/\/doi.org\/10.1186\/s12886-019-1245-4","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"14 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study adhered to the tenets of the Declaration of Helsinki. This study was approved by the Peking Union Medical College Hospital Review Board. The committee\u2019s reference number is S-K631. All participants provided their written informed consent to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"One of the authors, Youxin Chen, is a member of the editorial board of BMC ophthalmology. No other competing interests exist.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}